GlassScriptPhysician profile
Jacklyn Cupp
NPI 1598577215
$2,369.21
in general payments reported to CMS, 2019-2025
15 companies · $2,369 in 2025
The $2,369 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,369.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $414.21 | 2025 | Breztri, Tezspire, Airsupra |
| Abbvie INC. | $410.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $405.38 | 2025 | Ofev |
| Glaxosmithkline, LLC. | $345.78 | 2025 | Nucala, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $152.58 | 2025 | Auvelity |
| Gilead Sciences, INC. | $124.99 | 2025 | |
| Corcept Therapeutics | $121.19 | 2025 | Korlym |
| Novo Nordisk INC | $120.25 | 2025 | Ozempic |
| Amgen INC. | $82.75 | 2025 | Evenity, Tezspire, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.22 | 2025 | Relistor |
| Actelion Pharmaceuticals US, INC. | $37.18 | 2025 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $28.43 | 2025 | |
| Averitas Pharma INC. | $22.44 | 2025 | Qutenza |
| Radius Health, INC. | $20.83 | 2025 | Tymlos |
| Optinose US, INC. | $15.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacklyn Cupp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.